个性化文献订阅>期刊> Expert Opinion on Therapeutic Patents
 

Crystalline form of a neutrophil elastase inhibitor, 6-methyl-5-(1-methyl-1H-pyrazol-5-yl)-N-{[5-(methylsulfonyl)pyridin-2-yl]methyl}-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide p-toluene sulfonate - is it AZD-9668?: WO-2010094964

  作者 Norman, P  
  选自 期刊  Expert Opinion on Therapeutic Patents;  卷期  2011年21-2;  页码  277-280  
  关联知识点  
 

[摘要]This patent application claims a novel crystalline form (Form A) of a tosylate salt of a previously disclosed neutrophil elastase inhibitor. It also claims oral compositions of the salt and a process for the preparation of the crystalline form. The novel form is indicated to show improved physical properties relative to the free base. The claimed compound is evidently one of the elastase inhibitors currently being developed by AstraZeneca.

 
      被申请数(0)  
 

[全文传递流程]

一般上传文献全文的时限在1个工作日内